FDA Approves Immediate-Release Proton
Pump Inhibitor
On February 27, Santarus, Inc. announced that the FDA
approved its new drug application for Zegerid (omeprazole/sodium
bicarbonate) capsules, an immediate-release proton pump
inhibitor (PPI). Zegerid capsules were approved for
all of the indications the company was seeking.
Zegerid Capsules are indicated for the treatment of
heartburn and other symptoms associated with gastroesophageal
reflux disease, the short-term treatment (four to eight
weeks) of erosive esophagitis diagnosed by endoscopy
and active benign gastric ulcers, the short-term treatment
of active duodenal ulcers and for maintenance of healing
of erosive esophagitis (controlled studies do not extend
beyond 12 months).
To learn more about this new prescription medication,
please visit www.zegerid.com/index.asp.
|
